This phase II trial tests how well telisotuzumab vedotin and osimertinib works for the treatment of non small cell lung cancer that is growing, spreading, or getting worse (progressive) and for which no treatment is currently available (incurable). Telisotuzumab vedotin is a monoclonal antibody, called telisotuzumab, linked to a toxic agent, called vedotin. Telisotuzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of tumor cells, known as c-Met receptors, and delivers vedotin to kill them. Osimertinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving telisotuzumab vedotin and osimertinib may be effective for treating progressive, incurable non small cell lung cancer.

开始日期2026-02-19

申办/合作机构

Jonsson Comprehensive Cancer Center

[+1]

NCT06568939

/ Recruiting临床2期

A Phase 2, Open-Label, Randomized, Global Study of Three Telisotuzumab Vedotin Regimens in Subjects With Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer

Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-small cell lung cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung. The purpose of this study is to assess how safe telisotuzumab vedotin is in adult participants with NSCLC. Change in disease activity and adverse events will be assessed.
Telisotuzumab vedotin is an investigational drug being developed for the treatment of NSCLC. Participants will be randomly assigned a treatment of telisotuzumab vedotin in 1 of 3 arms at an 1:1:1 ratio. Each group receives intravenous (IV) infusion of telisotuzumab vedotin at different doses. Approximately 150 adult participants with c-Met overexpressing NSCLC will be enrolled in the study at approximately 80 to 90 sites worldwide.
Participants will receive IV telisotuzumab vedotin at 1 of 3 dose regimens as part of a 3 year study duration.
There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

开始日期2025-01-20

申办/合作机构

AbbVie, Inc.

NCT06093503

/ Withdrawn临床3期

Phase 3, Open-Label, Randomized, Controlled, Global Study of Telisotuzumab Vedotin (ABBV-399) Combined With Osimertinib vs Platinum-Based Chemotherapy in Subjects With c-Met Overexpressing (OE) EGFR Mutant, Locally Advanced/Metastatic Non-Squamous NSCLC After a First Progression on Prior Third Generation EGFR TKi Treatment

Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-small cell lung cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung. The purpose of this study is to assess how telisotuzumab vedotin in combination with osimertinib affects the disease state compared to standard of care in adult participants with locally advanced/metastatic non-squamous NSCLC that has a mutation in the epidermal growth factor receptor (EGFR) gene and that overexpresses the c-Met protein. Change in disease activity will be assessed.
Telisotuzumab vedotin is an investigational drug being developed for the treatment of NSCLC that overexpresses the c-Met protein. Participants are randomly placed in one of the two groups to receive telisotuzumab vedotin and osimertinib or standard of care chemotherapy. Approximately 250 adult participants with locally advanced/metastatic non-squamous NSCLC that has a mutation in the EGFR gene and that overexpresses the c-Met protein will be enrolled in the study in approximately 180 sites worldwide.
Participants will receive intravenous telisotuzumab vedotin every 2 weeks in combination with oral osimertinib tablets daily or standard of care chemotherapy (carboplatin/pemetrexed or cisplatin/pemetrexed as prescribed by the physician). Overall duration of the study is estimated to be approximately 47 months.
There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

开始日期2024-05-31

申办/合作机构

AbbVie, Inc.

100 项与维汀-特立妥珠单抗相关的临床结果

登录后查看更多信息

100 项与维汀-特立妥珠单抗相关的转化医学

登录后查看更多信息

100 项与维汀-特立妥珠单抗相关的专利（医药）

登录后查看更多信息

510

项与维汀-特立妥珠单抗相关的文献（医药）

2026-10-01·Trends in Cancer

Emerging landscape of antibody–drug conjugates in lung cancer: a clinical review

Review

作者: Chen, Neil ; Salgia, Ravi ; Lee, Matthew ; Pickett, Henry ; Arias-Romero, Javier ; Amini, Arya ; Malhotra, Jyoti ; Fricke, Jeremy ; Mambetsariev, Isa ; Bruno, Debora S

Lung cancer is a heterogeneous disease, and while targeted therapies and immunotherapies have improved patient outcomes, 5-year overall survival remains poor at approximately 20%. Antibody-drug conjugates (ADCs) target tumors using a targeted antibody that delivers a cytotoxic payload with clinically proven antitumor activity, and over a dozen ADCs are under consideration for solid tumors. Recent clinical trial data in metastatic non-small cell lung cancer have led to FDA approval of three ADCs: trastuzumab deruxtecan for patients with human epidermal growth factor receptor 2-mutated disease, telisotuzumab vedotin for MET-overexpressing tumors, and datopotamab deruxtecan for patients with epidermal growth factor receptor-mutated disease. In this article, we review the trajectory of individual ADC targets in lung cancer, describe the latest clinical trial results, and discuss future innovations in ADC therapies and potential mechanisms of resistance.

2026-10-01·VALUE IN HEALTH

Cost-Effectiveness of Telisotuzumab Vedotin-tllv for Previously Treated High c-Met Protein-Overexpressing Nonsquamous Non-Small Cell Lung Cancer in the United States

Article

作者: Weiss, Glen J

OBJECTIVES:

To estimate the incremental cost-effectiveness of telisotuzumab vedotin-tllv (teliso-V) versus docetaxel in previously treated high c-Met protein-overexpressing (≥50% of tumor cells with 3+ staining) advanced nonsquamous non-small cell lung cancer.

METHODS:

A partitioned survival model with monthly cycles and a five-year horizon was built from the US healthcare sector perspective. Individual time-to-event data were reconstructed from published Kaplan-Meier curves of the c-Met High subgroup (N=78) of LUMINOSITY and the CONTACT-01 docetaxel arm (N=180). Because individual covariate data were unavailable, a naive (unadjusted) indirect comparison was conducted. Seven parametric distributions were fit independently by arm; their median and range were the primary summary. The analysis was preregistered.

RESULTS:

The unadjusted overall survival hazard ratio favored teliso-V but was not statistically significant (HR 0.690; 95% CI 0.471-1.010). The median incremental cost-effectiveness ratio was approximately $2.0 million per QALY (range, $1.7-$2.2 million). Across 70,000 probabilistic iterations, cost-effectiveness was not achieved in any iteration at $50,000, $100,000, $150,000, or $200,000 per QALY. The threshold payment limit at $150,000 per QALY was approximately $1,209 per 100 mg (92% reduction).

CONCLUSIONS:

At the current Medicare Part B payment limit, telisotuzumab vedotin-tllv is unlikely to be cost-effective versus docetaxel in the US high c-Met protein-overexpressing population at conventional willingness-to-pay thresholds. The conclusion was robust to modeled survival extrapolation and parameter uncertainty. Because the comparison is unadjusted, comparative effectiveness remains uncertain pending randomized results.

2026-08-01·ESMO Open

Antibody–drug conjugates in selected solid tumours: a position statement update based on findings from the third workshop held by the ETOP IBCSG Partners Foundation

Article

作者: Fontana, E ; Van Cutsem, E ; Paz-Ares, L ; Argilés, G ; Powles, T ; Garon, E B ; Drago, J Z ; André, F ; Schmelzle, T ; Burgers, S ; Lopez-Rios, F ; Skynner, M J ; Stahel, R A ; Passaro, A ; Smit, E ; Klümper, N ; Smyth, E ; Loi, S ; Mountzios, G ; Reguart, N ; Azizi, A A ; Curigliano, G ; Remon, J ; Pistilli, B ; Peters, S ; Meyer, M-L ; Le Bescond, L ; Swanton, C ; Banerjee, S

The European Thoracic Oncology Platform (ETOP) International Breast Cancer Study Group (IBCSG) Partners Foundation initiated a series of workshops for experts to review current evidence and offer recommendations to guide future antibody-drug conjugate (ADC) research. Here, we summarise key findings from the third workshop, which included experts in various solid tumours, basic/translational research scientists and pharmaceutical industry representatives. Recent positive phase III trial data have further incorporated ADCs into the standard of care [e.g. lung: sacituzumab tirumotecan; breast: trastuzumab deruxtecan (T-DXd), sacituzumab govitecan, datopotamab deruxtecan; muscle-invasive bladder cancer: enfortumab vedotin; ovarian cancer: mirvetuximab soravastine; cervical cancer: tisotumab vedotin]. Thus, research priorities must be tailored according to tumour type, potentially focussing initially on settings where ADCs could replace chemotherapy. Many phase III ADC trials have been initiated based on positive phase I data and although these trials are larger than those conducted historically, prespecified criteria (e.g. patient numbers and magnitude of efficacy) should be met to justify proceeding directly to phase III. Importantly, although several ADCs have been successfully developed without mandatory biomarker selection, biomarker-driven ADC development enables rational patient selection, as illustrated by multiple ADCs (e.g. T-DXd, mirvetuximab soravtansine and telisotuzumab vedotin). The identification, development and validation of predictive biomarkers are therefore essential, particularly given several critical nuances, including the algorithms used to assess biomarker status and the type of specimen analysed, all of which may be influenced by temporal and spatial heterogeneity. Additional ADC research priorities include the optimisation of ADC constructs to enhance efficacy/tolerability and the identification of reliable ADC targets, including work to elucidate attributes of already-identified targets. Finally, considering the vast amount of ADC-related data being generated, artificial intelligence could be leveraged to analyse combined datasets and generate composite biomarkers, including tumour histology, optimal target expression thresholds, molecular alterations and activated pathways affecting payload activity and target function, to accelerate research.

364

项与维汀-特立妥珠单抗相关的新闻（医药）

2026-10-26

·药康生物GemPharmatech

靶点阳性，为何ADC仍可能无效？从体外评价到体内药效验证

ADC（Antibody-Drug Conjugate，抗体药物偶联物）通过抗体识别肿瘤相关靶点，将细胞毒性载荷递送至目标细胞，已成为肿瘤药物研发的重要方向。2025 年，FDA加速批准c-Met靶向ADC telisotuzumab vedotin（Emrelis），用于既往接受过系统治疗、c-Met蛋白高表达的非鳞状非小细胞肺癌患者。在 LUMINOSITY研究中，该药在符合c-Met高表达标准的患者中，客观缓解率（ORR）仅为35% [1]。这一结果提示，靶点表达虽是ADC药物评价与患者筛选的重要依据，却不足以单独预测治疗响应。为什么靶点阳性，ADC仍可能疗效有限？从靶点识别与结合、内化，到胞内转运、载荷释放及最终的细胞杀伤，ADC的作用涉及多个相互关联的环节。靶点表达的异质性、肿瘤细胞对载荷的敏感性，以及药物在肿瘤组织中的分布与暴露等因素，都可能影响最终的抗肿瘤效果[2]。因此，ADC的药效评价不能仅依赖靶点表达检测或单一体外实验。通过体外功能评价分析候选分子的细胞杀伤活性与作用特征，并结合体内药效验证，可从细胞水平与整体肿瘤环境两个维度，为候选 ADC的抗肿瘤活性提供更全面的评价依据。靶点阳性，不等于体外药效确定以c-Met靶向ADC ABBV-399为例，药康生物对8株肿瘤细胞系开展了靶点表达、受体内化及细胞杀伤的系列评价。结果显示，不同细胞系的c-Met表达水平差异显著，表面分子数从1,043个/细胞（NCI-H82）到499,170个/细胞（SNU-5），相差约500倍。然而，靶点表达水平并不能完全预测后续药物响应。例如，NCI-H1299的c-Met表达量为31,159个/细胞，但最大细胞杀伤率为0%。相比之下，低表达细胞系NCI-H446 的最大杀伤率达到90.60%，但其IC₅₀为 22.74 nM，明显高于SNU-5的0.05 nM（图 1，表 1）。图 1. ABBV-399 在8株c-Met表达水平不同的肿瘤细胞系中的体外细胞毒性。细胞经 ABBV-399、裸抗 Telisotuzumab 及游离载荷MMAE处理6天，图为浓度-细胞活力曲线（GC 法）。结果显示，ABBV-399的杀伤活性在不同细胞系间差异显著：在 SNU-5、Hs 746T 等细胞系中呈剂量依赖性杀伤，而在 NCI-H1299 等细胞系中几乎无杀伤；裸抗 Telisotuzumab 在各细胞系中均未显示明显细胞毒性。表 1. ABBV-399在8株c-Met表达水平不同的肿瘤细胞系中的体外杀伤活性注：NSCLC，非小细胞肺癌；SCLC，小细胞肺癌。为进一步探究这一现象的原因，我们补充开展了抗体结合与受体内化评价。FACS 结合实验显示，ABBV-399 在 SNU-5、Hs 746T与NCI-H1650 细胞上均能有效结合，结合特性与母体抗体Telisotuzumab相似，提示抗体与靶点的结合并非药效差异的限速步骤。而pHrodo标记的内化动力学实验则揭示了关键差异：三株c-Met阳性细胞系的48 h 最大内化率分别为76.86%（Hs 746T）、14.72%（NCI-H441）和1.16%（NCI-H1650）（图 2）。值得注意的是，NCI-H1650 虽表达36,603个c-Met分子 / 细胞且可被 ABBV-399 有效结合，却几乎不发生内化，细胞毒性载荷难以递送入胞，其最大杀伤率也相应较低 —— 这一结果直接解释了 "高表达却低杀伤" 的现象。图 2. ABBV-399 在c-Met阳性细胞系中的内化动力学（pHrodo 标记，FACS 检测）。三株细胞系的48 h 最大内化率分别为76.86%（Hs 746T）、14.72%（NCI-H441）与 1.16%（NCI-H1650）：NCI-H1650 虽为 c-Met 阳性且可被 ABBV-399 结合，但内化信号几乎不升高（上排为内化率，下排为 MFI）。这些结果表明，靶点表达是评价ADC活性的重要参考，但不能单独决定杀伤效果—内化效率、载荷释放及肿瘤细胞对载荷的敏感性等环节均可能影响药效，IC50与最大杀伤率需结合分析。系统的体外评价有助于候选分子筛选与模型选择，但要评估 ADC 在复杂肿瘤环境中的真实活性，仍需结合适宜的CDX 或PDX 模型开展体内药效验证。从细胞系到PDX：评估不同肿瘤背景下的体内药效体外评价主要关注分子与细胞层面的相互作用，而体内药效评价则进一步考察药物在完整动物模型中的抗肿瘤表现。与细胞系来源的CDX模型相比，患者来源的异种移植模型PDX能够在一定程度上保留原始肿瘤的组织学和分子特征，为研究不同患者肿瘤背景下的药物响应差异提供基础。对于ADC而言，肿瘤异质性是值得关注的因素之一。即使检测结果显示靶点表达较高，不同肿瘤细胞或同一肿瘤不同区域之间的表达水平仍可能存在差异。这类差异是否会影响体内药效，需要结合具体模型和实验结果进行判断。案例 1：HER2异质性表达的胃癌PDX（SC00344）药康生物在胃癌PDX模型 SC00344 中开展了Enhertu（DS-8201）的体内药效评价。该模型为单一患者来源，但不同肿瘤样本间的HER2 IHC 表达呈现明显差异（0、1+、3+ 等）（图 3）—— 这反映了 PDX 模型内部固有的肿瘤异质性，而非不同患者来源间的差异。DS-8201 单次静脉给药后，所有小鼠均达到研究方案定义的完全应答标准，个体肿瘤数据支持这一结果（图 3）。这一结果提示，即使同一模型内不同肿瘤样本的HER2 表达存在差异，ADC 仍可能表现出显著的体内抗肿瘤活性。值得注意的是，HER2阴性或低表达样本同样出现药物应答，其可能原因之一与Enhertu的旁观者效应有关：DS-8201 经 HER2 阳性细胞摄取并释放载荷后，游离载荷可扩散至邻近的HER2阴性 / 低表达肿瘤细胞并将其杀伤，从而在一定程度上弥补了靶点表达异质性带来的疗效差异。当然，样本间的应答差异仍不能仅以单一因素解释，还需结合样本来源、药效判定标准及其他相关实验信息进行综合分析。图 3. HER2异质性表达的胃癌PDX模型SC00344中Enhertu的体内药效评价。上图：5 个肿瘤样本的 HER2 IHC结果（评分 0、0、1+、3+、3+）；下图：肿瘤体积变化（左：各组群体数据；右：DS-8201 组个体小鼠应答）。案例 2：HER2高表达的ADC天然耐药肺癌 PDX（LC00167）肺癌PDX模型LC00167高表达HER2，但是对ADC药物DS-8201a（10 mpk）或RC-48（10 mpk）均表现出天然耐药（图 4）。这一案例提示：较高的HER2转录组表达水平并不必然对应理想的体内药效。TPM反映的是RNA丰度，不能直接等同于细胞膜表面HER2 蛋白密度，也不能预测 ADC 的有效内化与递送。进一步转录组分析发现，LC00167 中一组药物代谢 / 解毒酶基因 ——AKR1C1、AKR1C2、ALDH3A1、UGT1A6—— 的表达量在11例肺癌PDX中均居首位，明显高于同期评价的其他模型（图 4）。文献报道此类酶的上调可通过对细胞毒性 payload 进行还原、醛脱氢或葡萄糖醛酸化修饰而削弱其杀伤活性。据此推测，代谢酶介导的 payload 解毒可能是该模型对DS-8201a与RC-48响应有限的原因之一；但确切机制仍需结合 HER2蛋白定量、payload 胞内暴露量及ADC内化效率等实验进一步验证。图 4. HER2 阳性肺癌 PDX（LC00167）对DS-8201a与RC-48的体内响应及payload代谢酶表达特征。该样本 HER2 mRNA 表达为同批受检肺癌 / 胃癌 PDX 中最高（61.35 TPM），IHC 阳性（左上）。LC00167接种于NCG小鼠后，分别给予 DPBS、DS-8201a（10 mpk, i.p., QW×4）及 RC-48（10 mpk, i.p., QW×4），两种 HER2 ADC 均未显著抑制肿瘤生长，给药期间体重稳定（上排中、右）。RNA-seq 显示 LC00167 中AKR1C1、AKR1C2、ALDH3A1、UGT1A6 表达在受检 11 例肺癌 PDX 中居首位（红框，下排表格及热图），提示 payload 代谢 / 解毒增强可能与该模型对 ADC 治疗不敏感相关。两个案例从不同角度说明：无论肿瘤样本间存在靶点表达差异，还是模型整体呈现较高的靶点转录组表达，均不能仅凭单一表达指标判断ADC的体内响应。通过合适的肿瘤模型开展体内药效评价，并结合模型特征与药效结果进行分析，才能更全面地认识候选分子的抗肿瘤活性。从天然肿瘤异质性到可控模型：评价不同细胞群体的响应 PDX 模型有助于评价不同肿瘤背景下的ADC药效，但模型间复杂的生物学差异也增加了结果解读的难度。针对靶点表达异质性，混合肿瘤模型可将表达不同水平靶抗原的肿瘤细胞按预设比例混合接种，在相同宿主环境下评价不同细胞群体的响应。这一思路在 ADC 研究中已有先例：2024 年发表于Advanced Science的一项研究将HER2阳性与阴性肿瘤细胞混合接种，通过肿瘤体积、活体成像及终点肿瘤重量分析，评价了具有旁观者杀伤潜力的ADC T-VEd9的体内活性（图 5）[3]。图 5. 混合肿瘤模型中ADC的体内药效评价。研究将HER2阳性NCI-N87细胞与HER2阴性MDA-MB-231/teLuc 细胞按2:5的比例混合接种，建立HER2 异质性肿瘤模型，并通过肿瘤体积监测、活体生物发光成像、终点肿瘤重量及组织学分析，评价不同 ADC 的体内抗肿瘤活性及对HER2阴性肿瘤细胞的旁观者杀伤效应。数据引自Guo et al, Advanced Science, 2024（DOI: 10.1002/advs.202306309）。药康生物已开展混合肿瘤模型的构建，并在相关双靶项目中积累了模型设计与评价经验。结合公开文献中的 ADC 研究，该策略可根据候选分子的作用机制和研究目标进行针对性设计，为靶点异质性背景下的体内药效评价提供补充证据。需要指出的是，混合肿瘤模型并不能完全模拟患者肿瘤的天然异质性，也不能单独证明某一机制导致药物响应差异，其价值在于为特定科学问题提供相对可控的补充证据。从研发问题出发，制定更有针对性的 ADC体内评价策略不同 ADC 候选分子在靶点表达、内化能力、连接子与载荷特性，以及肿瘤异质性和耐药背景等方面存在差异。因此，体内药效评价应结合候选分子的作用机制与研发阶段，选择适配的肿瘤模型和评价终点（表2）。药效评价策略应围绕具体研发问题展开：CDX 适用于候选分子的初步药效筛选，PDX 可用于评估不同肿瘤背景下的药物响应；针对靶点异质性或耐药问题，可进一步采用混合肿瘤模型或经验证的耐药模型。必要时，结合体外功能评价、药代动力学（PK）、药效学（PD）及生物标志物分析，系统评估候选分子的体内药效及其影响因素。表 2. ADC 体内药效评价的模型选择围绕 ADC 临床前研究需求，药康生物已建立覆盖 HER2、c-Met、TROP2等靶点的 300+ CDX 细胞库，并积累了肺癌、胃癌、胰腺癌等多种肿瘤类型的PDX 及经验证的耐药模型资源，可为不同研发阶段的模型选择与药效评价提供支持（图 6）。靶点阳性是ADC发挥作用的起点，系统的体内评价则有助于进一步揭示其药效表现及潜在影响因素。药康生物可结合候选分子的特点与研发目标，提供针对性的临床前评价策略支持。图 6. 药康生物ADC临床前评价一站式解决方案。覆盖体外药理学、体内疗效、PK/PD与安全性评价四大模块，支持ADC从体外筛选到体内验证的完整评价流程。参考资料 [1] U.S. Food and Drug Administration. FDA grants accelerated approval to telisotuzumab vedotin-tllv for NSCLC with high c-Met protein overexpression[EB/OL].2025-05-14. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-telisotuzumab-vedotin-tllv-nsclc-high-c-met-protein-overexpression. [2] Colombo R, Tarantino P, Rich JR, et al. The Journey of Antibody–Drug Conjugates: Lessons Learned from 40 Years of Development. Cancer Discovery, 2024, 14(11): 2089–2108. DOI: 10.1158/2159-8290.CD-24-0708. [3] Guo Y, Shen Z, Zhao W, et al. Rational identification of novel antibody-drug conjugate with high bystander killing effect against heterogeneous tumors. Advanced Science, 2024, 11(13): e2306309. DOI: 10.1002/advs.202306309. 作者｜袁婉珺审核｜郭仕英编辑｜Kloe 就到这了，文末点个❤️给小编加个鸡腿吧~ 扫码立刻享受1v1咨询！关于药康生物江苏集萃药康生物科技股份有限公司（科创板代码：688046）是一家专注于实验动物小鼠模型研发、生产及非临床研究服务的国家级高新技术企业，同时是科技部认定的国家遗传工程小鼠资源库共建单位。依托CRISPR/Cas9、ES打靶等在内的基因编辑技术，公司建立了国际一流的基因修饰动物模型研发平台，拥有近3万种自主知识产权的基因工程小鼠模型品系，其中包括基因敲除/条件性敲除小鼠品系（"斑点鼠计划"）、药靶基因人源化模型、复杂疾病模型、系列免疫缺陷小鼠品系、无菌小鼠品系以及用于抗体药物发现的NeoMab®全人源抗体转基因小鼠，为全球科研机构、CRO公司及医药企业提供全面的模型资源支持。公司提供从基因编辑定制（包括转基因TG、基因敲除KO、基因敲入KI及点突变PM等）、模型繁育到功能药效分析的全流程一站式服务，服务范围涵盖肿瘤、自身免疫性疾病、代谢心血管疾病、神经退行性疾病、感染性疾病及罕见病等重点疾病领域，具体包括靶点验证、药效学评价和非GLP安全性评价等临床前研究。药康生物致力于成为全球实验动物模型领域的领导者，通过持续深化基因编辑技术的创新应用和资源整合，为生命科学研究和生物医药产业提供高质量的动物模型和技术服务，推动人类健康事业发展。点赞收藏分享

抗体药物偶联物临床结果临床研究

2026-10-25

·抗体密码

宜联cMET ADC首个临床结果披露！

AbAnalyzer Pro — 抗体序列分析平台已经重磅上线了《AbAnalyzer Pro ：让抗体设计更高效！》，九大核心功能，解决抗体一线研发中的痛点，助力抗体药物开发。 c-MET 是一个有潜力并且被反复尝试的靶点：在 30%–50% 的非小细胞肺癌（NSCLC）中过表达，克唑替尼等小分子在 MET 外显子 14 跳跃突变人群中有效，但更广泛的 MET 过表达人群长期缺乏好的药物治疗选择。ADC 是当前这条赛道上最被看好的形式——艾伯维的telisotuzumab vedotin 已凭 c-MET 过表达非鳞 NSCLC 的数据走完加速审批，新一代以拓扑异构酶 I 抑制剂（topo I payload）为载荷的 c-MET ADC 也已进入临床。YL211 是宜联生物的自研管线，2024 年 1 月授权罗氏全球开发，首付款及近期里程碑 5,000 万美元、潜在总额近 10 亿美元，这次 ESMO 罗氏公布了该分子的首个临床结构。 YL211 由新型 c-MET 单抗、高亲水性血浆稳定 linker 和新型 topo I 抑制剂载荷组成，DAR 8（药物抗体比，每个抗体偶联 8 分子载荷），基于宜联 TMALIN®（Tumor Microenvironment Activable LINker，肿瘤微环境可激活 linker）平台构建。值得注意的是，基于该平台的分子YL201（B7-H3 ADC）已经在国内申报上市。临床方面：剂量爬坡纳入标准治疗难治的晚期实体瘤（c-MET 全人群入组，不设表达阈值），YL211 静脉给药 Q3W（每 3 周），剂量 1.0–3.0 mg/kg。扩展回填（backfill）队列入组局部晚期不可切除或转移性 NSCLC（鳞癌与非鳞癌均收，c-MET 全人群），既往细胞毒系统治疗 ≤2 线，按 RDE 给药。数据截至 2026 年 7 月 1 日，中位随访 7.7 个月：剂量爬坡 27 例、NSCLC backfill 40 例，共 67 例。安全性方面：安全可评估人群 67 例。任何 TEAE（治疗期间出现的不良事件）97.0%，TRAE（治疗相关）95.5%；≥3 级 TEAE 64.2%。最常见的 TRAE 是恶心（59.7%）、中性粒细胞减少（49.3%）和贫血（44.8%）。胃肠毒性（恶心、呕吐、腹泻）以低级别为主，≥3 级均不超过 4.5%。血液学毒性呈剂量依赖，中性粒细胞减少等细胞减少在更高剂量时加重；血小板减少可控，临床出血罕见。发热性中性粒细胞减少仅 1 例（1.5%，G4），发生在 2.8 mg/kg——RDE 剂量下未见。间质性肺病（ILD）累计 3 例（4.5%）：1 例 G3 ILD + 2 例肺炎（G1、G2 各 1），这个水平和YL201相当。因 TEAE 停药 6 例（9.0%），减量 14 例（20.9%）。 MTD 与 RDE 爬坡 27 例中 4 例出现 DLT（剂量限制性毒性），2.6 mg/kg：G4 中性粒细胞计数下降（1 例）；2.8 mg/kg：G4 中性粒细胞减少 + G4 发热性中性粒细胞减少 + G4 血小板减少，全部发生在同一例患者；3.0 mg/kg：G4 输注相关反应（1 例）与 G3 腹泻（1 例） MTD 定为 2.6 mg/kg，RDE 为 2.0 和 2.6 mg/kg 两个剂量。爬坡期间 G-CSF 一级预防最初受限，仅 2.6 mg/kg 组高危患者允许使用。疗效方面：爬坡 ITT 人群（n=27）的整体数字不高：uORR（未确认客观缓解率）11.1%、cORR（确认客观缓解率）3.7%、DCR 74.1%。分层看，mCRC（n=16）uORR 18.8%、cORR 6.3%、DCR 81.3%。对一个 44.4% 患者既往 ≥3 线治疗、且近六成是 mCRC 的队列，DCR 站住 74.1% 说明药物有活性，但确认缓解只有 1 例（cORR 3.7%），mCRC 这个瘤种对 topo I ADC 的抵抗没有因为换平台而改变。 NSCLC backfill （n=40）疗效在剂量回填组中，uORR 与 cORR分别为40.0% 和 30.0% ，提示数据尚不成熟——中位随访 7.7 个月，部分缓解还在等待确认，最终 cORR 落点要看后续更新。2.6 mg/kg 的 cORR（34.5%）几乎是 2.0 mg/kg（18.2%）的两倍，DCR 差出近 30 个百分点。当然这是单臂、非随机的组间比较，样本量也不平衡（11 vs 29），只能说方向支持高剂量 RDE，不能当随机证据。总结从披露的数据来看，YL211临床毒性可控、与 topo I ADC 类药物预期一致；爬坡阶段各瘤种、各剂量均观察到早期活性；backfill 在两个 RDE 下均显示抗肿瘤活性，鳞癌与非鳞癌 NSCLC 都有缓解。但是后续还有部分问题需要进一步的数据披露才能深入解读，比如，poster中并未给出按 c-MET 表达水平的亚组分析，而 c-MET ADC 领域的历史经验（teliso-V 的 LUMINOSITY）是疗效集中在高表达人群，YL211 的 34.5% cORR 里高表达与低表达患者的贡献比例，是判断这个分子天花板的关键。另外，NSCLC的战场竞争非常激烈，mCRC 的 uORR 18.8% 能否随确认转化，决定这个分子的第二战场是否存在；我们已经建立抗体密码读者交流群，有兴趣的可以扫描下方二维码添加微信进群，请主动备注姓名-公司-职位（高校-专业），非诚勿扰！往期精彩回顾抗体密码文章合集双特异抗体平台靶点相关双特异抗体作用机制综述，行业概览抗体筛选技术相关公司技术汇总医药资讯因为你的分享、点赞、在看我足足的精气神儿！声明本公众号所发表文章以宣传知识为目的，因此不构成投资，病人用药等建议。如果文章侵您的权益及时联系小编进行删除！欢迎扫码交流/咨询/合作= 参考文献

2026-10-18

·PRNewswire

AbbVie to Present Data at the 2026 European Society for Medical Oncology (ESMO) Congress Highlighting Progress Across its Expanding Solid Tumor Portfolio

New and updated data across seven assets in lung, colorectal, ovarian, prostate and gastric cancers underscore the potential of AbbVie's oncology portfolio to address diverse patient needs through next-generation ADCs, combination approaches and precision medicine AbbVie's largest ESMO presence to date highlights longer-term survival data, combination and biomarker findings from multiple assets across various stages of development Presentations across investigational and approved medicines to feature Temab-A (telisotuzumab adizutecan), ABBV-706, ABBV-969, ABBV-1480 (RC148), alveltamig, Emrelis™ (telisotuzumab vedotin-tllv) and Elahere ®(mirvetuximab soravtansine-gynx) NORTH CHICAGO, Ill., Oct. 18, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that new and updated data from its broad solid tumor portfolio will be presented at the 2026 European Society for Medical Oncology (ESMO) Congress, taking place October 23-27 in Madrid, Spain. Spanning multiple tumor types, therapeutic modalities and stages of development, the presentations represent AbbVie's most expansive ESMO program to date. Collectively, the findings across Temab-A (telisotuzumab adizutecan), ABBV-706, ABBV-969, ABBV-1480 (RC148), alveltamig, Elahere® (mirvetuximab soravtansine-gynx) and Emrelis™ (telisotuzumab vedotin-tllv) demonstrate how AbbVie is leveraging its deep expertise in cancer biology to advance differentiated approaches that address the complexity and heterogeneity of solid tumors and help meet the diverse needs of cancer patients worldwide. "The data we are presenting at ESMO reflects the progress being made through AbbVie's disciplined, biology-driven approach to oncology innovation," said Daejin Abidoye, vice president, therapeutic area head of oncology, solid tumor and hematology, AbbVie. "Across multiple tumor types and stages of development, we are seeing encouraging evidence of longer-term clinical benefit, promising outcomes in biomarker-defined patient populations, and the potential of novel combinations and next-generation platforms. Together, these findings reinforce our strategy of translating scientific insights into differentiated treatment approaches with the potential to meaningfully improve outcomes for patients living with cancer." Selected findings from AbbVie's investigational solid tumor portfolio include updated clinical, survival and translational biomarker data across multiple antibody-drug conjugates (ADCs) and bispecific antibody programs, supporting continued development across a range of solid tumors: Temab-A Updated data continue to demonstrate encouraging clinical activity for Temab-A, an investigational, next-generation, c-Met-directed ADC with a novel topoisomerase 1 inhibitor (Top1i), across multiple solid tumor types. In a Phase 1 study of patients with previously treated advanced colorectal cancer (CRC), pooled data from the safety lead-in and dose-optimization cohorts showed that Temab-A (2.4 mg/kg) in combination with bevacizumab demonstrated a 30% overall response rate (ORR) and encouraging overall survival (OS) outcomes after a median follow-up of 18.2 months. Median OS reached 14.7 months with the combination (n=30), compared with 10.2 months for standard of care (n=20), regardless of c-Met protein expression level. No new safety signals were observed.1 This combination is being further evaluated in the ongoing global Phase 3 AndroMETa-CRC-560 study (NCT07525206). In an updated analysis from the ongoing Phase 1 study of Temab-A in non-squamous non-small cell lung cancer (NSCLC), the ORR was 50% with a median OS of 13.8 months in unselected patients with epidermal growth factor receptor (EGFR) wild-type disease (n=48). Among patients with EGFR-mutant disease (n=41), ORR was observed at 63% with a median OS of 16.2 months. In patients with EGFR wild-type disease, at the c-Met 3+, ≥25% expression threshold, median OS was approximately 19.2 months. As a monotherapy, Temab-A is being further evaluated, compared to the standard of care, in the global Phase 3 AndroMETa-Lung-167 study for previously treated patients with EGFR wild-type, non-squamous NSCLC (NCT07821684). In a separate post-hoc pooled exploratory analysis of 19 patients with EGFR-mutant NSCLC and baseline brain metastases, Temab-A achieved a 37% intracranial ORR, with a median duration of intracranial response of 19.8 months. No new safety signals were observed. AbbVie recently announced that Temab-A received two U.S. FDA Breakthrough Therapy Designations in CRC and NSCLC based, in part, on the data highlighted above. These designations further underscore the potential of Temab-A in addressing patient needs in these disease areas. ABBV-706: Updated Phase 1 findings reinforce the potential of ABBV-706, a SEZ6-directed ADC with a Top1i payload, in patients with relapsed/refractory (R/R) small cell lung cancer (SCLC), while new biomarker and translational findings further support SEZ6 as a promising therapeutic target. At the selected Phase 3 dose of 1.8 mg/kg (n=41), in a heavily pre-treated population, ABBV-706 achieved a 56% ORR and 12.4-month median OS in 2L+ SCLC patients; in the 2L-only subset (n=17), ORR increased to 82% and a 14.4-month median OS was observed. Safety was comparable to previously reported data. ABBV-706 is being further evaluated in an ongoing, randomized, open-label, multicenter Phase 3 trial versus standard of care in patients with R/R SCLC (NCT07365241). ABBV-969: Biomarker findings from a Phase 1 dose escalation study (NCT06318273) of ABBV-969 demonstrated robust molecular responses in heavily pretreated (median 5 prior lines of therapy) metastatic castration-resistant prostate cancer (mCRPC) patients (n=49). By cycle 3, 90% of patients achieved a ≥50% reduction in circulating tumor DNA (ctDNA) and 78% experienced circulating tumor cell conversion from unfavorable to favorable levels (≥5 to <5 cells). Among 27 patients with baseline PSMA PET assessments receiving ABBV-969 at doses ≥3 mg/kg, two were PSMA PET-negative per VISION criteria; both achieved a PSA50 response, including one patient with stable disease and one with a confirmed partial response.4 Together, these data further support the continued clinical development of ABBV-969, AbbVie's dual-targeting ADC approach to address tumor heterogeneity by simultaneously targeting two highly prevalent targets associated with mCRPC, prostate-specific membrane antigen (PSMA) and six-transmembrane epithelial antigen of prostate 1 (STEAP1), while delivering a Top1i payload. ABBV-1480 New data continue to support the development potential of ABBV-1480, a PD-1 × VEGF bispecific antibody, in lung cancer and other solid tumors. In a Phase 1 study of patients with first-line PD-L1-positive NSCLC, ABBV-1480 monotherapy (n=22) achieved a 61.9% ORR and a median progression-free survival (PFS) of 15.2 months.5 In previously treated NSCLC, ABBV-1480 combined with docetaxel at the 20 mg/kg dose (n=21) delivered a 66.7% ORR and 8.5-month median PFS.5 The most common grade ≥3 treatment-related adverse events for monotherapy were hypertension and proteinuria; for combination therapy, they were decreased neutrophil count, decreased white blood cell count and decreased lymphocyte count.5 ABBV-1480 continues to advance in clinical development, including the global Phase 3 AMUR-Lung-01 trial (NCT07756645) and a newly initiated combination study with Temab-A in NSCLC (NCT07874282). Details on key presentations at ESMO 2026 are available below and the full abstracts are available through the congress online program. Approved medicines and investigational assets referenced are being evaluated in ongoing clinical trials across multiple stages of development and disease areas, both as standalone therapies and in combination regimens. For more information on AbbVie's ongoing clinical trial programs, please visit ClinicalTrials.gov. Note: All presentation times are listed in local Madrid time. Temab-A, ABBV-706 and ABBV-969 are investigational medicines and are not approved by any health authority worldwide. Their safety and efficacy have not been established and are being evaluated in ongoing clinical studies. AbbVie holds exclusive rights from RemeGen to develop, manufacture and commercialize ABBV-1480 outside of Greater China. ABBV-1480 is an investigational medicine and is being evaluated in ongoing clinical studies. Alveltamig (ZG006) is an investigational medicine being developed by Suzhou Zelgen Biopharmaceuticals and has not been approved by any health authority worldwide. U.S. Prescribing Information for AbbVie Medicines Please see full Prescribing Information for ELAHERE® (mirvetuximab soravtansine-gynx) Please see full Prescribing Information for EMRELIS™ (telisotuzumab vedotin-tllv) About AbbVie AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas including immunology, neuroscience and oncology – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at . Follow @abbvie on LinkedIn, Facebook, Instagram, X and YouTube. About AbbVie in Oncology AbbVie is committed to elevating standards of care and bringing transformative therapies to patients worldwide living with difficult-to-treat cancers. We are advancing a dynamic pipeline of investigational therapies across a range of cancer types in both blood cancers and solid tumors. We are focusing on creating targeted medicines that either impede the reproduction of cancer cells or enable their elimination. We achieve this through various targeted treatment modalities and biology interventions, including small molecule therapeutics, antibody-drug conjugates (ADCs), immuno-oncology-based therapeutics, multispecific antibodies and novel CAR-T platforms. Our dedicated and experienced team joins forces with innovative partners to accelerate the delivery of potential breakthrough medicines.  Today, our expansive oncology portfolio comprises approved and investigational treatments for a wide range of blood cancers and solid tumors. We are evaluating more than 35 investigational medicines in multiple clinical trials across some of the world's most widespread and debilitating cancers. As we work to have a remarkable impact on people's lives, we are committed to exploring solutions to help patients obtain access to our cancer medicines. For more information, please visit . Forward-Looking Statements Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions and uses of future or conditional verbs, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, changes to laws and regulations applicable to our industry, the impact of global macroeconomic factors, such as economic downturns or uncertainty, international conflict, trade disputes and tariffs, and other uncertainties and risks associated with global business operations. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2025 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its Quarterly Reports on Form 10-Q and in other documents that AbbVie subsequently files with the Securities and Exchange Commission that update, supplement or supersede such information. AbbVie undertakes no obligation, and specifically declines, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law. 1 Cecchini M, Cruz-Correa M, Han S, et al. "Long-term follow up of Telisotuzumab Adizutecan (ABBV-400, Temab-A) in combination with bevacizumab (Bev) vs standard of care (SOC) in patients (pts) with 3L+ colorectal cancer (CRC): Updated results of a phase 1 study." Abstract presented at European Society for Medical Oncology Congress, 2026. Madrid, Spain. 2 Raimbourg J, Camidge R, Kim T, et al. " Telisotuzumab adizutecan (Temab-A) for EGFR-mutated (mut) nonsquamous non-small cell lung cancer (NSQ NSCLC): post hoc analysis from a Phase 1 first-in-human (FIH) study in patients (pts) with brain metastases." Abstract presented at Europoean Society for Medical Oncology Congress, 2026. Madrid, Spain. 3 Chiang A, Jahchan N, Faivre E, et al. "ABBV-706: A First-in-Class SEZ6-Targeted Topoisomerase 1 Inhibitor (Top1i)-Antibody-Drug Conjugate (ADC) With Robust Antitumour Activity in Relapsed/Refractory Small Cell Lung Cancer (R/R SCLC)." Abstract presented at European Society of Medical Oncology Congress, 2026. Madrid, Spain. 4 Peer A, Tolcher A, Joshua A, et al. "Baseline molecular characterization and responses associated with ABBV-969 treatment in patients with metastatic castration-resistant prostate cancer." Abstract presented at European Society of Medical Oncology Congress, 2026. Madrid, Spain 5 Yu J, Sun Y, Wen Q, et al. "RC148 (ABBV-1480) monotherapy or in combination with docetaxel in first- or second-line advanced non-small-cell lung cancer (NSCLC) without actionable genomic alterations (AGA): updated results from a Phase 1/2 study." Abstract presented at European Society of Medical Oncology Congress, 2026. Madrid, Spain. SOURCE AbbVie 21% more press release views with Request a Demo

临床结果临床1期临床3期ASCO会议突破性疗法

100 项与维汀-特立妥珠单抗相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D11344	-	-	DB15104

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
c-Met 阳性的非鳞状非小细胞肺癌	美国	AbbVie, Inc.	2025-05-14

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
局部晚期非鳞状非小细胞肺癌	临床3期	-	AbbVie, Inc.	2024-05-31
c-Met阳性食管腺癌	临床3期	美国	AbbVie, Inc.	2022-03-25
c-Met阳性食管腺癌	临床3期	中国	AbbVie, Inc.	2022-03-25
c-Met阳性食管腺癌	临床3期	日本	AbbVie, Inc.	2022-03-25
c-Met阳性食管腺癌	临床3期	阿根廷	AbbVie, Inc.	2022-03-25
c-Met阳性食管腺癌	临床3期	澳大利亚	AbbVie, Inc.	2022-03-25
c-Met阳性食管腺癌	临床3期	奥地利	AbbVie, Inc.	2022-03-25
c-Met阳性食管腺癌	临床3期	比利时	AbbVie, Inc.	2022-03-25
c-Met阳性食管腺癌	临床3期	巴西	AbbVie, Inc.	2022-03-25
c-Met阳性食管腺癌	临床3期	保加利亚	AbbVie, Inc.	2022-03-25

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ESMO2026	N/A	非小细胞肺癌二线	178	Telisotuzumab vedotin-tllv	獵繭襯齋窪淵夢觸憲觸(願壓衊築遞廠淵餘膚齋) = 簾蓋鹹夢繭鏇醖憲選醖壓繭觸淵艱築蓋鬱鑰構 (顧鏇衊醖鏇積鬱願繭淵, 38 ~ 88) 更多	积极	2026-10-23
NCT03539536 (LUMINOSITY, WCLC2026)	临床2期	非小细胞肺癌 c-Met protein overexpression	92	Teliso-V (EGFR wildtype + c-Met overexpression + NSCLC nonsquamous + 2L+ treatment)	鏇淵選壓淵鬱鏇築繭廠(夢顧鹹廠鑰鏇淵餘鬱艱) = The RRS was significantly associated with OS in both St: HR 5.5 (95% CI, 2.00-15.25; p=.0009); Sv: HR 16.3 (1.81-146.9; p=.0127). Kaplan-Meier analyses revealed significantly shorter survival in the high-risk group compared to the low-risk group in both St (P=.0009) and Sv (P=.0127). 壓蓋齋蓋鹹築淵範鹽簾 (鬱憲壓齋繭餘窪築獵製 )	积极	2026-09-12
NCT05513703 (CTgov)	临床2期	转移性非鳞状非小细胞肺癌 \| c-Met 阳性的非鳞状非小细胞肺癌	9	Telisotuzumab Vedotin	範願艱簾艱襯窪醖範獵 = 鑰膚構餘構鹽醖夢築構襯繭製顧憲顧膚網夢顧 (襯壓鑰鏇壓範顧衊觸製, 鏇積壓鹹願範簾繭製積 ~ 鏇憲網淵簾膚繭糧選簾) 更多	-	2025-10-24
NCT03539536 (LUMINOSITY, ESMO2025)	临床2期	c-Met 阳性的非鳞状非小细胞肺癌 c-Met protein overexpression	168	Teliso-V (pts with c-Met protein OE)	鑰遞憲選顧鬱構廠網夢(鏇醖窪鬱壓築願鏇餘選) = 夢顧遞積膚壓範襯鹹願積鏇鹽簾網艱齋餘餘衊 (願衊蓋積範築糧壓壓襯, 17.5 ~ 41.4)	积极	2025-10-17
				Teliso-V (pts with c-Met high)	鑰遞憲選顧鬱構廠網夢(鏇醖窪鬱壓築願鏇餘選) = 憲膚願遞獵網衊廠壓構積鏇鹽簾網艱齋餘餘衊 (願衊蓋積範築糧壓壓襯, 18.7 ~ 46.3)
NCT03539536 (LUMINOSITY, WCLC2025)	临床2期	鳞状细胞肺癌三线 \| 二线 MET overexpression	168	Telisotuzumab Vedotin 1.9 mg/kg (c-Met OE Total；No PN ≥3)	鬱襯簾願鏇遞網壓觸憲(觸遞鬱築醖襯窪範艱廠) = 糧醖餘鹽範鏇夢憲遞窪構膚鹹窪糧壓膚顧憲觸 (壓觸積襯艱製鏇淵構繭 ) 更多	积极	2025-09-08
				Telisotuzumab Vedotin 1.9 mg/kg (c-Met OE Total；PN ≥3)	鬱襯簾願鏇遞網壓觸憲(觸遞鬱築醖襯窪範艱廠) = 鹹選醖獵衊簾範獵築鬱構膚鹹窪糧壓膚顧憲觸 (壓觸積襯艱製鏇淵構繭 ) 更多
NCT03539536 (LUMINOSITY, ASCO2025)	临床2期	c-Met阳性非小细胞肺癌二线 c-Met overexpression \| KRAS \| BRAF ... 更多	83	Teliso-V 1.9 mg/kg	鹹繭蓋襯糧衊蓋築遞鏇(壓鹽築餘壓顧積積築鑰) = 窪簾鏇製餘遞醖鹽醖糧觸顧壓餘鬱鹽窪範遞築 (窪鏇願壓憲積膚艱夢鏇 ) 更多	积极	2025-05-30
				Placebo	齋顧憲鑰範獵淵製壓餘(餘憲獵衊蓋範觸構顧鑰) = 製築襯壓蓋窪鬱積選築齋鹽願餘積製鑰積衊餘 (廠鏇遞艱鑰窪觸願構構 ) 更多
NCT03539536 (LUMINOSITY, FDA_CDER) 人工标引	临床2期	c-Met阳性非小细胞肺癌 MET Overexpression	84	EMRELIS (high c-Met protein overexpression)	觸膚淵範遞壓願淵製觸(齋鹽衊齋齋築觸簾鬱觸) = 襯鹽糧選製遞構鬱簾夢鬱鹽繭淵膚獵構顧憲繭 (遞願餘蓋鹽獵願願淵鏇, 24 ~ 46) 更多	积极	2025-05-14
NCT03539536 (LUMINOSITY, ESMO_ELCC2025) 人工标引	临床2期	c-Met阳性非小细胞肺癌 \| 晚期非小细胞肺癌 EGFR Gene Mutation Negative \| MET Overexpression	172	Telisotuzumab vedotin 1.9 mg/kg (c-Met high: ≥50% 3+)	窪構簾齋衊鏇艱選製積(網淵壓繭淵簾淵遞膚壓) = 憲鏇簾製窪淵選構網遞鬱襯醖糧製蓋膚夢繭齋 (鬱膚鏇鹹齋鏇膚糧製蓋, 24.5 ~ 45.7) 更多	积极	2025-03-26
				Telisotuzumab vedotin 1.9 mg/kg (c-Met intermediate [int]: 25 to <50% 3+)	窪構簾齋衊鏇艱選製積(網淵壓繭淵簾淵遞膚壓) = 範鬱膚網醖憲壓齋鏇醖鬱襯醖糧製蓋膚夢繭齋 (鬱膚鏇鹹齋鏇膚糧製蓋, 15.2 ~ 34.3) 更多
NCT02099058 (Pubmed \| Ann Oncol) 人工标引	临床1期	非小细胞肺癌二线 EGFR Mutation \| MET Overexpression	38	Telisotuzumab vedotin + osimertinib	願醖獵鹽鏇糧獵鹽鬱壓(醖齋憲鑰願築觸顧淵憲) = peripheral sensory neuropathy (50%), peripheral edema (32%), and nausea (24%) 糧艱選繭獵襯願觸網醖 (鏇壓壓選鹽廠繭蓋願壓 ) 更多	积极	2025-01-01
NCT03539536 (LUMINOSITY, CSCO2024)	临床2期	c-Met 阳性的非鳞状非小细胞肺癌 c-Met protein overexpression	24	Telisotuzumab vedotin (c-Met High + Ethnically Chinese)	願襯窪積積壓鑰顧鬱糧(淵廠構艱淵蓋鹽衊膚襯) = 鹹衊夢膚餘壓糧鹹構觸範簾窪艱築簾衊夢鹹醖 (糧襯選憲糧積獵淵衊簾, 19.2 ~ 74.9) 更多	积极	2024-09-25
				Telisotuzumab vedotin (c-Met Intermediate + Ethnically Chinese)	願襯窪積積壓鑰顧鬱糧(淵廠構艱淵蓋鹽衊膚襯) = 範鬱鏇憲蓋顧艱製繭壓範簾窪艱築簾衊夢鹹醖 (糧襯選憲糧積獵淵衊簾, 2.3 ~ 51.8) 更多